Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program
Susan M Abughosh1, Stephen J Kogut2
1Department of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences (MCPHS), MA, USA; 2Department of Pharmacy Practice, Program in Pharmacoepidemiology and Pharmacoeconomics, University of Rhode Island (URI), College of Pharmacy, RI, USA
Objective: To compare levels of persistency between cholinesterase inhibitors (ChEIs) among a Medicaid patient population of older adults.
Methods: Survival analysis was used to assess differences in discontinuation between ChEIs (donepezil versus rivastigmine and galantamine), and for difference in patient gender, age, race, and care setting.
Results: Rates of discontinuation increased from 42.7% (95% CI = 39.9–45.5) at 12 months to 84.8% (95% CI = 82.3–87.3) at 24 months. In multivariate models, no significant difference in discontinuation existed prior to 365 days. However, patients dispensed donepezil were less likely to discontinue as compared with users of the other two ChEIs after the first year (RR = 0.70; CI = 0.499–0.983; p < 0.04). Patients of white race were less likely to discontinue (RR = 0.549; 95% CI = 0.43–0.82; p = 0.0015), while gender, care setting, and age were not associated with discontinuation.
Conclusions: One-year persistence rates were similar between different ChEIs. Among patients persisting with ChEI medication for at least 12 months, users of donepezil were slightly more likely to continue to persist at 24 months. Nearly half of patients failed to persist with ChEI therapy for at least 12 months. Our findings underscore the limitations of the ChEI medications and the urgent need for effective and tolerable therapeutic options for patients having dementia.
Keywords: persistence, elderly, alzheimer’s disease, cholinesterase inhibitors, medicaid
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Published Date: 28 October 2015
Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M
Published Date: 11 September 2015
Rocchi A, Chabot I, Glennie J
Published Date: 3 June 2015
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology
Aprile G, Leone F, Giampieri R, Casagrande M, Marino D, Faloppi L, Cascinu S, Fasola G, Scartozzi M
Published Date: 22 May 2015
Schroyen S, Adam S, Jerusalem G, Missotten P
Published Date: 31 December 2014
Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population
Benekli M, Yalcin S, Ozkan M, Elkiran ET, Sevinc A, Cabuk D, Coskun HS, Oksuzoglu B, Bayar B, Akbulat A, Ozet A
Published Date: 15 December 2014
Loong HH, Yeo W
Published Date: 16 April 2014
Rosenberg AR, Wolfe J
Published Date: 24 March 2013
Cantrell MA, Ruble K
Published Date: 30 May 2011
Gena Kanas, Libby Morimoto, Fionna Mowat, et al
Published Date: 24 February 2010